# Pfizer **Source:** https://geo.sig.ai/brands/pfizer **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** pfizer.com **Last Updated:** 2026-04-14 ## Summary Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring. ## Company Overview Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak. Pfizer's core commercial portfolio extends across oncology, rare disease, internal medicine, and vaccines. Eliquis (apixaban, co-promoted with Bristol-Myers Squibb) remains the world's best-selling anticoagulant; Ibrance leads in CDK4/6 inhibitor breast cancer therapy; Vyndaqel/Vyndamax dominates the ATTR-CM (transthyretin cardiomyopathy) market where it has achieved blockbuster status. The Prevnar pneumococcal vaccine franchise and Nimenrix meningococcal vaccines anchor a diversified global vaccine portfolio. Pfizer's "Fit-to-Win" restructuring program targets $4 billion in annual cost savings by 2025, realigning R&D investments toward the highest-value pipeline opportunities post-Seagen integration. In 2025-2026, Pfizer confronts significant patent cliff risks: Eliquis faces generic competition beginning in 2026-2028, representing roughly $7 billion in annual U.S. revenues at risk. The Seagen ADC platform is the primary offense against this cliff, with Padcev already generating $1 billion-plus in annual revenues for metastatic urothelial cancer. Competitive pressures come from AstraZeneca (Enhertu in ADCs), Eli Lilly (oncology expansion), and Merck (Keytruda franchise). Activist investor Starboard Value took a stake in late 2024 and has pressed for more aggressive cost cuts and strategic review. Pfizer's GLP-1 obesity drug danuglipron failed Phase 2 trials in 2023, leaving the company without a direct entry in the fast-growing obesity therapeutics market dominated by Eli Lilly and Novo Nordisk. ## Frequently Asked Questions ### What does Pfizer do? Pfizer is a leading global biopharmaceutical company that discovers, develops, manufactures, and distributes innovative medicines and vaccines to treat and prevent diseases. The company focuses on therapeutic areas including oncology, infectious diseases, cardiometabolic conditions, immunology, and rare diseases, with a mission to deliver breakthroughs that change patients' lives worldwide. ### Who are Pfizer's customers and target market? Pfizer's customers include patients worldwide who receive prescribed medicines and vaccines through healthcare providers, hospitals, pharmacies, and government health programs. The company serves healthcare professionals, insurance companies, government agencies, and healthcare systems globally. Pfizer's products address diverse patient populations from infants receiving vaccines to elderly patients managing chronic conditions. ### When was Pfizer founded? Pfizer was founded in 1849 by Charles Pfizer and Charles F. Erhart, two cousins who immigrated from Germany to Brooklyn, New York. The company celebrated its 175th anniversary in 2024, marking nearly two centuries of pharmaceutical innovation from its humble beginnings as a small chemical company to becoming one of the world's leading biopharmaceutical corporations. ### Where is Pfizer based? Pfizer is headquartered in New York City, with its global headquarters located in Manhattan. The company operates worldwide with significant research, development, and manufacturing facilities across the United States, Europe, Asia, and other regions, maintaining a global presence to serve patients in countries around the world. ### How much funding has Pfizer raised? As a publicly traded company founded in 1849 (NYSE: PFE), Pfizer has not raised venture capital funding. Instead, the company has grown through reinvestment of profits, strategic acquisitions, and public market financing. In 2024, Pfizer invested $10.8 billion in internal R&D, paid down $7.8 billion in debt, and returned $9.5 billion to shareholders through dividends. ### What makes Pfizer different from competitors? Pfizer differentiates itself through its robust R&D investment ($10.8B in 2024), diverse therapeutic portfolio spanning oncology to vaccines, strategic acquisitions like the $43B Seagen deal that doubled its cancer pipeline, and commitment to AI-driven drug development. The company's 175-year history, strong balance sheet, and goal to double oncology patients treated by 2030 demonstrate its long-term strategic vision and innovation leadership. ### Who are Pfizer's main competitors? Pfizer's primary competitors include Johnson & Johnson, Roche, Novartis, Merck, AbbVie, Bristol Myers Squibb, and AstraZeneca in various therapeutic areas. In oncology, competitors include Roche and Bristol Myers Squibb. In vaccines, Merck, GSK, and Sanofi are key competitors. The pharmaceutical industry is highly competitive with companies competing on innovation, patent portfolios, clinical trial success, and commercial execution. ### How can I contact Pfizer? Pfizer can be contacted through its corporate website at www.pfizer.com, which provides contact information for investor relations, media inquiries, medical information, and patient support. Healthcare professionals can access medical information services, while patients can find product information and support programs. For general inquiries, Pfizer's headquarters contact information is available on their website. ### Is Pfizer hiring? Yes, Pfizer regularly hires across its global operations with over 88,000 employees worldwide. Career opportunities are available at careers.pfizer.com in areas including research and development, clinical trials, manufacturing, commercial operations, regulatory affairs, and corporate functions. Pfizer emphasizes diversity and inclusion in hiring and offers competitive benefits and professional development opportunities. ### What's the latest news about Pfizer? Pfizer's most recent major news includes completing the $7 billion acquisition of Metsera in November 2025 to add GLP-1 weight management candidates, entering a $1.25 billion licensing deal with 3SBio for cancer treatment in May 2025, and receiving 14 FDA approvals in 2024. The company reported strong 2024 results with $63.6B revenue and announced plans to advance nine new Phase 3 oncology trials in 2025. ### What is Pfizer's market position? Pfizer is one of the world's largest pharmaceutical companies by revenue and market capitalization, ranking among the top 5 globally. In 2024, the company generated $63.6 billion in revenue with strong positions in oncology (following the Seagen acquisition), vaccines (Prevnar family), and cardiovascular (Eliquis). Pfizer is a leader in antibody-drug conjugates and maintains a robust pipeline with significant oncology focus. ### What are Pfizer's future plans? Pfizer's strategic priorities include advancing nine new pivotal Phase 3 oncology trials in 2025 to achieve its goal of doubling cancer patients treated by 2030, executing a cost realignment program to deliver $4.5B in savings by end of 2025, investing in AI-driven drug development, and focusing on oncology, infectious diseases, and cardiometabolic therapeutic areas as core growth drivers. The company projects 2025 revenues of $61-64 billion and plans balanced capital allocation including potential share repurchases. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*